{"id":"W2055346449","doi":"10.1016/s1470-2045(14)71205-7","title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1354,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Castration; Urology; Abiraterone; Enzalutamide; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}